Rss Top Picks FeedRss Daily Feed| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
| There are 6 registered members and 56 guests viewing the site. | Follow us on Twitter | Rss Top Picks Feed | Rss Daily Feed |
StockResearchPortal.com |
|
| BUY on WEAKNESS | 60.570 | Karl Berger | Largest biotech stock in the US. He prefers biotech to pharma. This one is quite a reasonable company but thinks the markets are a little overdone at these levels. You won't go too far wrong but try to get it in the mid-to low $50's. | 2009-10-14 | |
| BUY | 59.500 | Gordon Reid | Bio Pharma. Just came out with some promising test results on a bone cancer drug. Trading at about 15X earnings, which is very reasonable. Decent dividend. | 2009-07-08 | |
| Comment | 49.880 | Mike S. Newton, CIM FCSI | Very interested in the biotech space. This one has been sitting unnoticed for a little while. Even more interesting would be the Biotech HLDRs (BBH-N). (See comments under BBH-N). | 2009-06-11 | |
| TOP PICK | 46.090 | Brian Acker, CA | Model $59.79. Drugs have been showing up. Get it before the numbers come in. Market selling off in light of expected earnings. | 2009-04-21 | |
| DON'T BUY | 55.960 | David Burrows | Stocks that under perform in a bull market tend to under perform more in a bear market. They have a decelerating growth rate. Expect there will be sales reduction over the next year. | 2007-06-22 | |
| Comment | 59.650 | John Manley | From a technical perspective, he would look for it to carve out a double bottom, or a higher low. | 2007-04-16 | |
| DON'T BUY | 60.010 | David Cockfield | Can't get enthused about the pharmaceutical markets. The amount of government action, the pressures, the lawsuits, etc. makes it a high-risk area. | 2007-03-15 | |
| SELL | 63.980 | David Burrows | There are concerns that the growth level in the business indicates there has been a dissatisfaction and lack of interest in pharmaceutical and drug companies. Below the 200 day moving average. | 2006-06-27 | |
| BUY | 76.190 | David Baskin | One of the great pharmaceutical stories. Fabulous company. The whole industry has been lackluster for last 2/3 years. This has been driven by patent litigation and lawsuits. Probably a reasonable price right now. | 2006-02-01 | |
| BUY | 75.200 | David Burrows | The biotech sector has done well this year. This stock has held up well during the market correction. Looks like it has started into a longer climb higher. Because of the current market risk, you have to pick your entries. | 2005-10-26 | |
| SELL | 82.680 | Brian Acker, CA | Model price has been the same at $53.30. The increase in the stock price has been a little overdone. | 2005-08-04 | |
| BUY | 58.950 | Ray Steele | Likes the stock. The sector has been weak over the last few months. Has a pretty full pipeline of stuff that could surprise us. Trades at a reasonable multple. | 2005-03-17 | |
| DON'T BUY | 59.810 | Kevin Vandermeer, B.Comm, CFA | Majority of money is from 3 products. Want's more diversificaion. Good balance sheet though. | 2005-03-11 | |
| TOP PICK | 54.360 | Samuel D. Isaly | A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that. | 2004-08-13 | |
| TOP PICK | 54.360 | Nicholas Sargen | Likes the health-care sector. One of the top companies. Has underperformed for a long time, but they are willing to be patient. | 2004-08-13 | |
| TOP PICK | 55.730 | Alan Blake | Under a cloud. Driven down because of generic drugs and imports from Canada. Medicare will be onerous. Powerful balance sheet. | 2004-07-16 | |
| TOP PICK | 56.650 | Nicholas Sargen | Health care should outperform in a rising interest rate environment. A premier company. Likes the pipeline that it has. Out-of-favor right now. | 2004-05-14 | |
| TOP PICK | 57.140 | John Sinkins, CFA | (A top pick in Feb/04. Down a bit.) This sector has great prospects on a going forward basis but will be volatile on a short-term basis. A leader in their field. Good growth prospects. | 2004-05-11 | |
| TOP PICK | 59.510 | Nicholas Sargen | 2004-04-02 | ||
|
| |||||
| TOP PICK | 62.760 | John Sinkins, CFA | A leading biotech company. Trading at 22 X next year's earnings. Pretty cheap for this quality of a company. | 2004-03-09 | |
| BUY | 61.870 | John Sinkins, CFA | A very mature biotech company. Expects about 10/15% revenue growth and about 20/25% earnings growth. Trading at a low multiple. | 2003-12-29 | |
| PAST TOP PICK | 61.150 | David Burrows | (A top pick July 15/03. Down 13.7%.) Sold the stock in the summer. | 2003-11-03 | |
| TOP PICK | 61.190 | John Sinkins, CFA | Has made some good acquisitions in the last couple of years, which has propped up their product line. 25 X next year's earnings. | 2003-11-03 | |
| BUY | 60.300 | Paul O'Neil | They don't have the problem of drugs going off patent. The stock can go much higher. Dropping currently because the sector is pulling it down. | 2003-10-22 | |
| PAST TOP PICK | 68.930 | David Burrows | Was a top pick on Jun 4/03. Up 7%.) The leader in bio techs. Has grown its earnings every year since 1994. | 2003-07-22 | |
| TOP PICK | 71.540 | David Burrows | A lot of drug products in the pipeline. Cash flow is growing. | 2003-07-15 | |
| TOP PICK | 67.210 | David Burrows | Has made money every year going back to 1994. Good cash flow. | 2003-07-02 | |
| TOP PICK | 64.490 | David Burrows | A safe way of investing in biotechs. Has held up through poor periods. Has a broad pipeline of products. | 2003-06-04 | |
| BUY | 61.880 | Peter Arender, CFA | Has better earnings and price momentum than Biogen going forward. Likes both Biogen and Amgen, but Amgen is their first choice. | 2003-05-26 | |
| PAST TOP PICK | 60.970 | Brian Acker, CA | (Was a top pick on Apr 7. Up 7.4%) Still likes. | 2003-05-06 | |
| TOP PICK | 61.300 | Brian Acker, CA | Three drugs are coming out which are blockbusters. | 2003-04-30 | |
| TOP PICK | 58.410 | Brian Acker, CA | Expects the S&P to drop to 820 and this stock could drop. Buy on pull backs. Has three block buster drugs on the way. | 2003-04-07 | |
| BUY on WEAKNESS | 51.520 | Neil Murdock | Very successful biotech. Big growth. May be a little high. | 2003-01-13 | |
| BUY on WEAKNESS | 45.641 | Andrew McCreath | 18/20% growth for the next few years. Would prefer to buy in the $30's. | 2002-08-13 | |
| HOLD | 35.830 | David Baskin | The biotech sector is down. A high quality company. | 2002-07-03 | |
| DON'T BUY | 56.400 | Brad Willock | Doesn't like their run at Immunex. | 2002-01-02 | |
| BUY on WEAKNESS | 59.060 | Brian Acker, CA | A little high now. Would buy at $50. | 2001-12-28 | |
| DON'T BUY | 58.330 | Michelle Calpin | Too expensive. | 2001-12-19 | |
| BUY | 62.710 | Gavin Graham | A good buy and hold. Good products. Volatile. | 2001-07-31 | |
|
| |||||
| BUY | 57.160 | Glenn Paradis, BA, CFA | Good broad spectrum. Volatile. | 2001-07-06 | |
| PAST TOP PICK | 68.200 | John Sinkins, CFA | (Was a top pick on Feb 22/01 down 3%)Still likes. A good entry point. Likes better than Hemasol. | 2001-06-06 | |
| TOP PICK | 70.063 | John Sinkins, CFA | Biotechs should grow substantially. A core company in the biotech sector. Has a pipeline. Profitable. | 2001-02-22 | |
| BUY on WEAKNESS | 58.688 | Noah Blackstein, B.A., CFA | Likes. In late stage production | 2001-01-08 | |
| DON'T BUY | 54.000 | Noah Blackstein, B.A., CFA | Facing risks on patents and drugs not that good. | 2000-10-30 |
